Actively Recruiting
First-in-Human Randomized Study of DCY636 Safety and Pharmacokinetics in Healthy Volunteers and in Moderate to Severe Atopic Dermatitis
Led by Novartis Pharmaceuticals · Updated on 2026-08-19
63
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating DCY636, a new drug, in a first-in-human study to assess its safety, tolerability, and behavior in the body. This study includes healthy volunteers and people with moderate to severe atopic dermatitis, a skin condition, to support future development of DCY636. It is a randomized, placebo-controlled, double-blind study with a treatment purpose. Participants receive either single ascending doses of DCY636 or placebo in healthy volunteers Part 1, or multiple doses in people with moderate to severe atopic dermatitis Part 2. Different dose levels are tested in separate cohorts, including six dose levels in healthy participants and one dose level in the atopic dermatitis group. Participants are randomly assigned to either DCY636 or placebo in both parts of the study. During the study, participants undergo safety monitoring including tracking adverse events and serious adverse events for up to approximately 202 days in healthy volunteers and 301 days in the atopic dermatitis group. Researchers also measure drug levels in the body and immune response against DCY636. Participants attend scheduled visits for assessments, laboratory tests, and symptom evaluations to monitor the drugs effects and safety over the study period.
CONDITIONS
Brief Title
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here